Advertisement

Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment

  • 4 Accesses

Opinion statement

Sinonasal malignancies pose a significant challenge in management due to their low incidence, biologic diversity, and significant symptom burden. Even though surgery remains the primary therapeutic modality, a multi-modality approach has been shown to benefit a significant proportion of patients and its success depends largely on stage and histologic type. Non-surgical approaches such as novel radiation approaches as well as intensification with systemic therapy hold promise in altering the organ preservation rate as well as overall survival for patients. Practice changing randomized trials to test these novel modalities are overdue and desperately needed.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

References and Recommended Reading

    Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

    1. 1.

      Roush GC. Epidemiology of cancer of the nose and paranasal sinuses: current concepts. Head Neck Surg. 1979;2(1):3–11.

    2. 2.

      Muir CS, Nectoux J. Descriptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses. Clin Otolaryngol Allied Sci. 1980;5(3):195–211.

    3. 3.

      Maghami E, Kraus DH. Cancer of the nasal cavity and paranasal sinuses. Expert Rev Anticancer Ther. 2004;4(3):411–24. https://doi.org/10.1586/14737140.4.3.411.

    4. 4.

      Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34(6):877–85. https://doi.org/10.1002/hed.21830.

    5. 5.

      Zheng W, McLaughlin JK, Chow WH, Chien HT, Blot WJ. Risk factors for cancers of the nasal cavity and paranasal sinuses among white men in the United States. Am J Epidemiol. 1993;138(11):965–72. https://doi.org/10.1093/oxfordjournals.aje.a116816.

    6. 6.

      El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol. 2005;29(10):1367–72.

    7. 7.

      Bhattacharyya N. Factors affecting survival in maxillary sinus cancer. J Oral Maxillofac Surg. 2003;61(9):1016–21. https://doi.org/10.1016/s0278-2391(03)00313-6.

    8. 8.

      Torjussen W. Occupational nasal cancer caused by nickel and nickel compounds. Rhinology. 1985;23(2):101–5.

    9. 9.

      Luce D, Leclerc A, Morcet JF, Casal-Lareo A, Gerin M, Brugere J, et al. Occupational risk factors for sinonasal cancer: a case-control study in France. Am J Ind Med. 1992;21(2):163–75.

    10. 10.

      Schwaab G, Julieron M, Janot F. Epidemiology of cancers of the nasal cavities and paranasal sinuses. Neurochirurgie. 1997;43(2):61–3.

    11. 11.

      Devaraja K, Sikka K, Kumar R, Thakar A. Sinonasal malignancies: long term follow up after surgical management-an analysis of outcomes. Indian J Otolaryngol Head Neck Surg. 2015;67(1):28–33. https://doi.org/10.1007/s12070-014-0742-2.

    12. 12.

      Dulguerov P, Allal AS. Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg. 2006;14(2):67–72. https://doi.org/10.1097/01.moo.0000193177.62074.fd.

    13. 13.

      Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck. Bmj. 2002;325(7368):822–7. https://doi.org/10.1136/bmj.325.7368.822.

    14. 14.

      Ansa B, Goodman M, Ward K, Kono SA, Owonikoko TK, Higgins K, et al. Paranasal sinus squamous cell carcinoma incidence and survival based on surveillance, epidemiology, and end results data, 1973 to 2009. Cancer. 2013;119(14):2602–10. https://doi.org/10.1002/cncr.28108.

    15. 15.

      Carlton DA, David Beahm D, Chiu AG. Sinonasal malignancies: endoscopic treatment outcomes. Laryngoscope Investig Otolaryngol. 2019;4(2):259–63. https://doi.org/10.1002/lio2.249.

    16. 16.

      • Husain Q, Joshi RR, Cracchiolo JR, Roman BR, Ganly I, Tabar V, et al. Surgical management patterns of sinonasal malignancy: a population-based study. J Neurol Surg B Skull Base. 2019;80(4):371–9. https://doi.org/10.1055/s-0038-1675233 Assessment of over 10,000 patients from National Cancer Data Base showing sinonasal cancers managed with endoscopic surgery had comparable outcomes to open resection.

    17. 17.

      Nicolai P, Battaglia P, Bignami M, Bolzoni Villaret A, Delu G, Khrais T, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol. 2008;22(3):308–16. https://doi.org/10.2500/ajr.2008.22.3170.

    18. 18.

      Higgins TS, Thorp B, Rawlings BA, Han JK. Outcome results of endoscopic vs craniofacial resection of sinonasal malignancies: a systematic review and pooled-data analysis. Int Forum Allergy Rhinol. 2011;1(4):255–61. https://doi.org/10.1002/alr.20051.

    19. 19.

      Wellman BJ, Traynelis VC, McCulloch TM, Funk GF, Menezes AH, Hoffman HT. Midline anterior craniofacial approach for malignancy: results of en bloc versus piecemeal resections. Skull Base Surg. 1999;9(1):41–6. https://doi.org/10.1055/s-2008-1058171.

    20. 20.

      Lango MN, Topham NS, Perlis CS, Flieder DB, Weaver MW, Turaka A, et al. Surgery in the multimodality treatment of sinonasal malignancies. Curr Probl Cancer. 2010;34(5):304–21. https://doi.org/10.1016/j.currproblcancer.2010.07.001.

    21. 21.

      Sayed Z, Migliacci JC, Cracchiolo JR, Barker CA, Lee NY, McBride SM, et al. Association of surgical approach and margin status with oncologic outcomes following gross total resection for sinonasal melanoma. JAMA Otolaryngol Head Neck Surg. 2017;143(12):1220–7. https://doi.org/10.1001/jamaoto.2017.2011.

    22. 22.

      Varelas AN, Eggerstedt M, Ganti A, Tajudeen BA. Epidemiologic, prognostic, and treatment factors in sinonasal diffuse large B-cell lymphoma. Laryngoscope. 2019;129(6):1259–64. https://doi.org/10.1002/lary.27639.

    23. 23.

      Goepfert H. The vex and fuss about nasal vestibule cancer. Head Neck. 1999;21(5):383–4.

    24. 24.

      Thorup C, Sebbesen L, Dano H, Leetmaa M, Andersen M, Buchwald C, et al. Carcinoma of the nasal cavity and paranasal sinuses in Denmark 1995–2004. Acta Oncol. 2010;49(3):389–94. https://doi.org/10.3109/02841860903428176.

    25. 25.

      Wang K, Zanation AM, Chera BS. The role of radiation therapy in the management of sinonasal and ventral skull base malignancies. Otolaryngol Clin N Am. 2017;50(2):419–32. https://doi.org/10.1016/j.otc.2016.12.014.

    26. 26.

      Huang D, Xia P, Akazawa P, Akazawa C, Quivey JM, Verhey LJ, et al. Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2003;56(1):158–68. https://doi.org/10.1016/s0360-3016(03)00080-4.

    27. 27.

      Dirix P, Vanstraelen B, Jorissen M, Vander Poorten V, Nuyts S. Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(4):998–1004. https://doi.org/10.1016/j.ijrobp.2009.09.067.

    28. 28.

      Patel SH, Wang Z, Wong WW, Murad MH, Buckey CR, Mohammed K, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol. 2014;15(9):1027–38. https://doi.org/10.1016/s1470-2045(14)70268-2.

    29. 29.

      Ghorbani M, Jia SB, Khosroabadi M, Sadoughi HR, Knaup C. Evaluation of the effect of soft tissue composition on the characteristics of spread-out Bragg peak in proton therapy. J Cancer Res Ther. 2017;13(6):974–80. https://doi.org/10.4103/0973-1482.220420.

    30. 30.

      van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. Oncologist. 2011;16(3):366–77. https://doi.org/10.1634/theoncologist.2010-0171.

    31. 31.

      • Dagan R, Bryant C, Li Z, Yeung D, Justice J, Dzieglewiski P, et al. Outcomes of Sinonasal Cancer treated with proton therapy. Int J Radiat Oncol Biol Phys. 2016;95(1):377–85. https://doi.org/10.1016/j.ijrobp.2016.02.019 Single institution review from the University of Florida analyzing disease outcomes after proton therapy for sinonasal cancer.

    32. 32.

      • Russo AL, Adams JA, Weyman EA, Busse PM, Goldberg SI, Varvares M, et al. Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2016;95(1):368–76. https://doi.org/10.1016/j.ijrobp.2016.02.042 Single institution review from Massachusetts General Hospital reporting data on long-term outcomes in patients with sinonasal squamous cell carcinoma treated with proton therapy.

    33. 33.

      Zenda S, Kohno R, Kawashima M, Arahira S, Nishio T, Tahara M, et al. Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2011;81(5):1473–8. https://doi.org/10.1016/j.ijrobp.2010.08.009.

    34. 34.

      Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–43. https://doi.org/10.1200/jco.2013.54.6309.

    35. 35.

      Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704. https://doi.org/10.1056/NEJMoa071028.

    36. 36.

      LoRusso P, Tapazoglou E, Kish JA, Ensley JF, Cummings G, Kelly J, et al. Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University. Cancer. 1988;62(1):1–5. https://doi.org/10.1002/1097-0142(19880701)62:1<1::aid-cncr2820620102>3.0.co;2-f.

    37. 37.

      Bjork-Eriksson T, Mercke C, Petruson B, Ekholm S. Potential impact on tumor control and organ preservation with cisplatin and 5-fluorouracil for patients with advanced tumors of the paranasal sinuses and nasal fossa. A prospective pilot study. Cancer. 1992;70(11):2615–20. https://doi.org/10.1002/1097-0142(19921201)70:11<2615::aid-cncr2820701108>3.0.co;2-g.

    38. 38.

      Hanna EY, Cardenas AD, DeMonte F, Roberts D, Kupferman M, Weber R, et al. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg. 2011;137(1):78–81. https://doi.org/10.1001/archoto.2010.231.

    39. 39.

      Hoffmann TK. Systemic therapy strategies for head-neck carcinomas: current status. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2012;11:Doc03. https://doi.org/10.3205/cto000085.

    40. 40.

      Lee MM, Vokes EE, Rosen A, Witt ME, Weichselbaum RR, Haraf DJ. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999;5(4):219–23.

    41. 41.

      Licitra L, Locati LD, Cavina R, Garassino I, Mattavelli F, Pizzi N, et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol. 2003;14(3):367–72. https://doi.org/10.1093/annonc/mdg113.

    42. 42.

      Mendenhall WM, Amdur RJ, Morris CG, Kirwan J, Malyapa RS, Vaysberg M, et al. Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope. 2009;119(5):899–906. https://doi.org/10.1002/lary.20196.

    43. 43.

      Guntinas-Lichius O, Kreppel MP, Stuetzer H, Semrau R, Eckel HE, Mueller RP. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol. 2007;33(2):222–8. https://doi.org/10.1016/j.ejso.2006.10.033.

    44. 44.

      Kang JH, Cho SH, Kim JP, Kang KM, Cho KS, Kim W, et al. Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis. J Oral Maxillofac Surg. 2012;70(7):1717–23. https://doi.org/10.1016/j.joms.2011.06.221.

    45. 45.

      Kim JH, Lee YS, Chung YS, Jang YJ, Kim SB, Lee SW, et al. Treatment outcomes of concurrent chemoradiotherapy for locally advanced sinonasal squamous cell carcinoma: a single-institution study. Acta Otolaryngol. 2015;135(11):1189–95. https://doi.org/10.3109/00016489.2015.1061697.

    46. 46.

      Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu AJ, Wolden SL, et al. Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2008;72(3):763–9. https://doi.org/10.1016/j.ijrobp.2008.01.038.

    47. 47.

      Resto VA, Chan AW, Deschler DG, Lin DT. Extent of surgery in the management of locally advanced sinonasal malignancies. Head Neck. 2008;30(2):222–9. https://doi.org/10.1002/hed.20681.

    48. 48.

      Chen NX, Chen L, Wang JL, Wang JY, Yan F, Ma L, et al. A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus. Jpn J Clin Oncol. 2016;46(8):727–34. https://doi.org/10.1093/jjco/hyw064.

    49. 49.

      Danesh-Sani SA, Sarafraz A, Chamani M, Derakhshandeh H. Paranasal sinuses malignancies: a 12-year review of clinical characteristics. Med Oral Patol Oral Cir Bucal. 2016;21(5):e626–30. https://doi.org/10.4317/medoral.21170.

    50. 50.

      Le QT, Fu KK, Kaplan M, Terris DJ, Fee WE, Goffinet DR. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems. Cancer. 1999;86(9):1700–11.

    51. 51.

      Mierzwa ML, Nyati MK, Morgan MA, Lawrence TS. Recent advances in combined modality therapy. Oncologist. 2010;15(4):372–81. https://doi.org/10.1634/theoncologist.2009-S105.

    52. 52.

      •• Robin TP, Jones BL, Gordon OM, Phan A, Abbott D, McDermott JD, et al. A comprehensive comparative analysis of treatment modalities for sinonasal malignancies. Cancer. 2017;123(16):3040–9. https://doi.org/10.1002/cncr.30686 Recent retrospective analysis of data obtained from National Cancer Data Base of treatment outcomes for over 11,000 patients with sinonasal malignances.

    53. 53.

      Rosen A, Vokes EE, Scher N, Haraf D, Weichselbaum RR, Panje WR. Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993;119(7):743–6. https://doi.org/10.1001/archotol.1993.01880190039008.

    54. 54.

      • Pare A, Blanchard P, Rosellini S, Auperin A, Gorphe P, Casiraghi O, et al. Outcomes of multimodal management for sinonasal squamous cell carcinoma. J Craniomaxillofac Surg. 2017;45(8):1124–32. https://doi.org/10.1016/j.jcms.2017.05.006 Single institutional data from France suggesting multimodal therapy combining neoadjuvant chemotherapy followed by wide resection and adjuvant radiation therapy seems to provide promising results in management of SCC SNC.

    55. 55.

      Porceddu S, Martin J, Shanker G, Weih L, Russell C, Rischin D, et al. Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck. 2004;26(4):322–30. https://doi.org/10.1002/hed.10388.

    56. 56.

      Suarez C, Llorente JL, Fernandez De Leon R, Maseda E, Lopez A. Prognostic factors in sinonasal tumors involving the anterior skull base. Head Neck. 2004;26(2):136–44. https://doi.org/10.1002/hed.10358.

    57. 57.

      Bossi P, Perrone F, Miceli R, Cantu G, Mariani L, Orlandi E, et al. Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. Oral Oncol. 2013;49(5):413–9. https://doi.org/10.1016/j.oraloncology.2012.12.011.

    58. 58.

      Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol. 2004;22(24):4901–6. https://doi.org/10.1200/jco.2004.05.071.

    59. 59.

      Reiersen DA, Pahilan ME, Devaiah AK. Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg. 2012;147(1):7–14. https://doi.org/10.1177/0194599812440932.

    60. 60.

      Castelnuovo P, Turri-Zanoni M, Battaglia P, Antognoni P, Bossi P, Locatelli D. Sinonasal malignancies of anterior skull base: histology-driven treatment strategies. Otolaryngol Clin N Am. 2016;49(1):183–200. https://doi.org/10.1016/j.otc.2015.09.012.

    61. 61.

      Bell D, Hanna EY. Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers. Expert Rev Anticancer Ther. 2013;13(3):285–96. https://doi.org/10.1586/era.13.1.

    62. 62.

      Mourad WF, Hauerstock D, Shourbaji RA, Hu KS, Culliney B, Li Z, et al. Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. Am J Clin Oncol. 2013;36(6):584–8. https://doi.org/10.1097/COC.0b013e31825eb3a5.

    63. 63.

      Musy PY, Reibel JF, Levine PA. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope. 2002;112(8 Pt 1):1450–5. https://doi.org/10.1097/00005537-200208000-00023.

    64. 64.

      Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, et al. Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol. 2019;37(6):504–12. https://doi.org/10.1200/jco.18.00353.

    65. 65.

      Day TA, Beas RA, Schlosser RJ, Woodworth BA, Barredo J, Sharma AK, et al. Management of paranasal sinus malignancy. Curr Treat Options in Oncol. 2005;6(1):3–18.

    66. 66.

      Lian B, Si L, Cui C, Chi Z, Sheng X, Mao L, et al. Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013;19(16):4488–98. https://doi.org/10.1158/1078-0432.Ccr-13-0739.

    67. 67.

      Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 2011;305(22):2327–34. https://doi.org/10.1001/jama.2011.746.

    68. 68.

      Valsecchi ME, Sato T. The potential role of sunitinib targeting melanomas. Expert Opin Investig Drugs. 2013;22(11):1473–83. https://doi.org/10.1517/13543784.2013.837449.

    69. 69.

      Ganti A, Raman A, Shay A, Kuhar HN, Auger SR, Patel T, et al. Treatment modalities in sinonasal mucosal melanoma: a national cancer database analysis. Laryngoscope. 2019. https://doi.org/10.1002/lary.27995.

    70. 70.

      Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope. 1992;102(8):843–9. https://doi.org/10.1288/00005537-199208000-00001.

    71. 71.

      Eich HT, Hero B, Staar S, Micke O, Seegenschmiedt H, Mattke A, et al. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma. Strahlenther Onkol. 2003;179(4):233–40. https://doi.org/10.1007/s00066-003-1089-x.

    72. 72.

      Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, et al. Esthesioneuroblastoma: continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg. 2006;132(2):134–8. https://doi.org/10.1001/archotol.132.2.134.

    73. 73.

      Callender TA, Weber RS, Janjan N, Benjamin R, Zaher M, Wolf P, et al. Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg. 1995;112(2):252–7. https://doi.org/10.1016/s0194-59989570246-6.

    74. 74.

      Edmonson JH. Chemotherapeutic approaches to soft tissue sarcomas. Semin Surg Oncol. 1994;10(5):357–63.

    75. 75.

      Khan MN, Husain Q, Kanumuri VV, Boghani Z, Patel CR, Liu JK, et al. Management of sinonasal chondrosarcoma: a systematic review of 161 patients. Int Forum Allergy Rhinol. 2013;3(8):670–7. https://doi.org/10.1002/alr.21162.

    76. 76.

      van den Berg H, Schreuder WH, de Lange J. Osteosarcoma: a comparison of jaw versus nonjaw localizations and review of the literature. Sarcoma. 2013;2013:316123. https://doi.org/10.1155/2013/316123.

    77. 77.

      Scangas GA, Eloy JA, Lin DT. The role of chemotherapy in the management of sinonasal and ventral skull base malignancies. Otolaryngol Clin N Am. 2017;50(2):433–41. https://doi.org/10.1016/j.otc.2016.12.015.

    Download references

    Contributions

    Dr. Mody contributed as a primary author and Dr. Saba contributed as senior author and editor.

    Author information

    Correspondence to Nabil F. Saba MD, FACP.

    Ethics declarations

    Conflict of Interest

    Mayur D. Mody declares that he has no conflict of interest. Nabil F. Saba has received research funding from Bristol-Myers Squibb, Exelixis, and Champions Oncology; has served on advisory boards for Merck, Bristol-Myers Squibb, Rakuten, and GlaxoSmithKline; and has served on a data safety monitoring committee for Amgen.

    Human and Animal Rights and Informed Consent

    This article does not contain any studies with human or animal subjects performed by any of the authors.

    Additional information

    Publisher’s note

    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

    This article is part of the Topical Collection on Head and Neck Cancer

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Mody, M.D., Saba, N.F. Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment. Curr. Treat. Options in Oncol. 21, 4 (2020) doi:10.1007/s11864-019-0696-4

    Download citation

    Keywords

    • Sinonasal cancer
    • Sinonasal malignancies
    • Multimodal therapy
    • Head and neck cancer
    • Systemic therapy
    • Chemotherapy